No approved treatment for this lung disease cough. A new pill now heads into Phase 3 trials

robot
摘要生成中

Trevi Therapeutics announced the completion of its End-of-Phase 2 meeting with the FDA, gaining alignment for its development program for Haduvio (nalbuphine ER oral) to treat idiopathic pulmonary fibrosis (IPF)-related chronic cough. The company plans to conduct two pivotal Phase 3 trials in parallel, starting in Q2 2026 and H2 2026, alongside remaining Phase 1 studies to support a New Drug Application (NDA). These trials will evaluate a 54 mg BID dose, using 24-hour cough frequency as the primary endpoint.

此页面可能包含第三方内容,仅供参考(非陈述/保证),不应被视为 Gate 认可其观点表述,也不得被视为财务或专业建议。详见声明
  • 赞赏
  • 评论
  • 转发
  • 分享
评论
请输入评论内容
请输入评论内容
暂无评论